WallStreetZenWallStreetZen

NASDAQ: IRON
Disc Medicine Inc Stock Forecast, Predictions & Price Target

Analyst price target for IRON

Based on 4 analysts offering 12 month price targets for Disc Medicine Inc.
Min Forecast
$56.00-8.21%
Avg Forecast
$67.75+11.05%
Max Forecast
$75.00+22.93%

Should I buy or sell IRON stock?

Based on 4 analysts offering ratings for Disc Medicine Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IRON stock forecasts and price targets.

IRON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-08-14
lockedlocked$00.00+00.00%2023-06-12
lockedlocked$00.00+00.00%2023-06-12
lockedlocked$00.00+00.00%2023-06-12

1 of 1

Forecast return on equity

Is IRON forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is IRON forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

IRON revenue forecast

What is IRON's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$15.1M
Avg 2 year Forecast
$68.9M
Avg 3 year Forecast
$159.7M

IRON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IRON$61.01$67.75+11.05%Strong Buy
CLDX$31.43$53.00+68.63%Buy
PNT$14.06$13.00-7.54%Buy
CPRX$14.15$25.00+76.68%Strong Buy
RYZB$25.40$31.33+23.36%Strong Buy

Disc Medicine Stock Forecast FAQ

Is Disc Medicine Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: IRON) stock is to Strong Buy IRON stock.

Out of 4 analysts, 2 (50%) are recommending IRON as a Strong Buy, 2 (50%) are recommending IRON as a Buy, 0 (0%) are recommending IRON as a Hold, 0 (0%) are recommending IRON as a Sell, and 0 (0%) are recommending IRON as a Strong Sell.

If you're new to stock investing, here's how to buy Disc Medicine stock.

What is IRON's revenue growth forecast for 2026-2028?

(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Disc Medicine's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast IRON's revenue for 2026 to be $364,882,569, with the lowest IRON revenue forecast at $278,339,135, and the highest IRON revenue forecast at $451,426,004. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $1,663,999,702, with the lowest IRON revenue forecast at $755,595,396, and the highest IRON revenue forecast at $3,760,595,874.

In 2028, IRON is forecast to generate $3,855,129,790 in revenue, with the lowest revenue forecast at $3,075,490,527 and the highest revenue forecast at $5,144,083,803.

What is IRON's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: IRON) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is IRON's Price Target?

According to 4 Wall Street analysts that have issued a 1 year IRON price target, the average IRON price target is $67.75, with the highest IRON stock price forecast at $75.00 and the lowest IRON stock price forecast at $56.00.

On average, Wall Street analysts predict that Disc Medicine's share price could reach $67.75 by Aug 14, 2024. The average Disc Medicine stock price prediction forecasts a potential upside of 11.05% from the current IRON share price of $61.01.

What is IRON's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: IRON) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.